Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Cognition Therapeutics, Inc. (CGTX)
Company Research
Source: Yahoo! Finance
- 1Q 2024 Capital Raise Extends Cash Runway Through May 2025 - - Webcast Conference Call Scheduled Today at 8:00 a.m. ET - PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. Management will host a live webcast conference call at 8:00am ET to review 2023 accomplishments. Details of the call are provided below. A number of important clinical milestones were achieved in 2023, including the completion of enrollment in the Company's Phase 2 SHINE Study in people with mild-to-moderate Alzheimer's disease. In addition, the company initiated clinical studies in early Alzheimer's disease and dry age-related macular degeneration (dry AMD). Cognition scientists published two manuscripts and made
Show less
Read more
Impact Snapshot
Event Time:
CGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGTX alerts
High impacting Cognition Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CGTX
News
- Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies [Yahoo! Finance]Yahoo! Finance
- Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy BodiesGlobeNewswire
- Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease [Yahoo! Finance]Yahoo! Finance
- Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s DiseaseGlobeNewswire
- Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's [Seeking Alpha]Seeking Alpha
CGTX
Earnings
- 8/8/23 - Beat
CGTX
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- CGTX's page on the SEC website